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Background: Desaturation and elongation are critical processes in endogenous
metabolic fatty acid pathways. Zinc (Zn) is a cofactor for desaturases and elongases
enzymes. There is limited evidence regarding the relationships between biomarkers of
Zn status, nutritional intake, plasma phospholipid fatty acid profile and clinical outcomes
among patients undergoing hemodialysis (HD).
Objective: To examine the relationships between dietary and serum levels of Zn and
Cu/Zn ratio and to explore associations of these micronutrients with PUFA profile and
estimated desaturase and elongase enzyme activities in serum phospholipids among
HD patients.
Methods: This study included 40 adult patients undergoing hemodialysis treatment.
Repeated 24-h recalls were applied for dietary intake assessment. Serum concentration
of Zn and Cu were determined using inductively coupled plasma mass spectrometry and
fatty acid composition by gas-liquid chromatography. Desaturase and elongase activities
were calculated from product-precursor fatty acid ratios.
Results: Inadequate dietary Zn intake was found in 55% of HD patients. They all
had serum Zn concentration below the reference value of 60 µg/dL (mean 38.8 ±
7.72 µg/dL). Adequate zinc intake was accompanied with significantly higher intake of
energy, total fats, SFA, MUFA and proteins. There was no correlation between Zn serum
status and Zn intake estimates. Serum Cu/Zn ratio was high, (2.76 ± 0.68), directly and
significantly associated with HD period, CRP, BMI, VFA, and inversely with Kt/V, albumin,
iron, and iPTH. The n-6/n-3 ratio in plasma phospholipids was elevated (12.25 ± 3.45)
and patients with inadequate Zn intake had lower n-3 PUFA intake and status compared
to those with adequate intake. Serum Zn concentrations were inversely correlated with
linoleic/dihomo-γ-linolenic acid ratio (LA/DGLA) (p = 0.037), related to D6-desaturase
activity (p = 0.033) and directly with DGLA relative abundances (p = 0.024). Cu status
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was inversely associated with EPA level (p = 0.03) and estimates of elongase activity
(p = 0.001). Furthermore, positive relationship was found between the Cu/Zn ratio and
determined elongase value (p = 0.01).
Conclusion: Findings of this study underpin the high prevalence of Zn deficiency and
inadequate n-3 PUFA intake and status among subjects undergoing HD. The results
obtained indicate that the assessment of Zn status should be a standard parameter
of nutritional status screening in HD patients while emphasizing the importance
of Cu/Zn determination. Although further research is warranted, Zn and-n-3 PUFA
supplementation in HD patients might be beneficial for the prevention and attenuation
of adverse health outcomes
Keywords: zinc, fatty acid, Cu/Zn ratio, LA/DGLA, hemodialysis
INTRODUCTION
Chronic kidney diseases (CKD) is recognized as a global
public health concern with significant clinical, economic, and
humanistic burdens. Patients on hemodialysis treatment have
a high incidence of cardiovascular diseases (CVD) and an
increased mortality rate (1). Risk factors such as dyslipidemia,
insulin resistance, disturbances in fatty acid metabolism,
increased oxidative stress, and inflammation are considered
accountable for the endothelial impairment and cumulative
alterations of vascular function in hemodialysis patients (2). Zinc
is an essential micronutrient with numerous roles is fundamental
biologic processes. Due to unique antioxidant and anti-
inflammatory properties and implications in enzyme activity,
membrane stabilization and apoptosis inhibition, zinc is essential
for endothelial integrity (3). Consequently, zinc deficiency could
lead to severe endothelial damage and amplification of the
detrimental impact of certain fatty acids such as linoleic acid,
and inflammatory cytokines on vascular function (4). There is
accumulating evidence that dysregulation of zincmetabolism and
suboptimal status could be associated with the development of
CVD (5). The risk of atherosclerosis in zinc-deficient patients
with renal failure plays an important role in the progression and
complications of CKD (6, 7). Lower zinc levels are related to
end-stage renal disease (8).
Zinc deficiency increases oxidative stress and a cytokine-
mediated inflammatory process leading to atherosclerotic
complications (3). Among patients with CKD, deterioration of
kidney function causes impaired elimination of an array of
uremic toxins. They have been shown to promote inflammatory
state and aggravate the production of reactive oxygen species.
Abbreviations: AA, arachidonic acid; ALA, alfa-linolenic acid; Alb, albumin;
BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein;
Cu, copper; CVD, cardiovascular disease; D5D, 1-5-desaturase; D6D, 1-
6-desaturase; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid;
DPA, docosapentaenoic acid; ELO, elongase; EPA, eicosapentaenoic acid; HD,
hemodialysis; Hg, hemoglobin; ICP-MS, inductively coupled plasma mass
spectrometry; iPTH, intact parathyroid hormone; LA, linoleic acid; MAC,mid arm
circumference; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty
acids; RDI, recommended daily intake; sCr, serum creatinine; SFA, saturated fatty
acids; Tg, Triglyceride; TC, total cholesterol; VAI, visceral adiposity index; VFA,
visceral fat area; WC, waist circumference; Zn, zinc.
The damaging effect of these processes is intensified by the
hemodialysis procedure itself, and, in such circumstances, zinc
exerts a significant role in antioxidant systems. Numerous
studies underpinned Cu/Zn-superoxide dismutase gradient as an
effective oxidative stress marker for the evaluation of progressive
renal damage (8). It has been proposed that the serum Cu/Zn
ratio reflects the reciprocal reaction of Cu and Zn better than
serum Cu or Zn concentrations separately (9, 10). Furthermore,
it was found that the Cu/Zn-ratio significantly increases with
aging (11). This biomarker, used also for the evaluation of
oxidative stress burden, is associated with a higher risk of incident
infection (10) and elevated cardiovascular mortality rate in the
elderly population (12–14). Zinc, as an antioxidant and anti-
inflammatory mediator, regulates the function of lymphocytes,
making the body’s immune system less susceptible to various
infections (15–17). Recently, the protective role of zinc in
vulnerable groups for COVID-19 such as hemodialysis patients
has been mentioned (18).
Several studies confirm a high prevalence of zinc deficiency
in hemodialysis patients (5, 19–23). This could be caused by
multiple factors such as: inadequate nutritional intake due to
protein restriction, reduced gastrointestinal dietary absorption,
increased zinc excretion or loss into the dialysate, altered
cellular and tissue distribution, as well as phosphate-binder drugs
interaction and oral iron supplementation (16, 24–26). The main
inhibitor of intestinal zinc absorption is phytate, which is found
in unrefined cereals, pulses, oilseeds, and nuts. The evidence
indicates that zinc deficiency could lead to erythropoietin-
resistant anemia and increased susceptibility to renal damage in
patients with diabetes (27, 28).
Previous studies, including ours, have reported disturbances
in the proportion of serum fatty acids in hemodialysis patients
particularly with lower n-3 polyunsaturated fatty acids (PUFA)
and higher monounsaturated fatty acids (MUFA) content
compared to healthy subjects (29–32). Depending on stages of
CKD severity, there is an increase of MUFA and a gradual
progressive decrease in the content of n-3 and n-6 PUFA, which
contributes to the occurrence of dyslipidemia in CKD patients
(33). The mechanism by which disturbance in fatty acid profile
such as decline of n-3 PUFA/arachidonic acid (AA) ratio in
hemodialysis still remains unclear (34). Endogenous fatty acid
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metabolism is regulated by D5, D6, and D9 desaturase enzymes.
Zinc is a cofactor for desaturases and elongases enzymes (35).
Therefore, the alterations of zinc serum levels could affect
the activities of these enzymes and consequently modulate the
regulation of fatty acid metabolism. Recently, the linoleic (LA)/
dihomo-γ-linoleic acid (DGLA) ratio has been proposed as a
novel biomarker of zinc status (36, 37). There is a scarcity in
available scientific data regarding the interaction between zinc
intake and status and PUFA fatty acid in CKD.
Thus, the aim of the present study was to examine
the relationship between dietary zinc intake, its serum
concentrations and Cu/Zn ratio and to explore associations of
these micronutrients with PUFA profile in serum phospholipids




This was a cross-sectional study conducted at the Department of
Hemodialysis, Clinic of Nephrology, Military Medical Academy,
Belgrade, Serbia.
Study Population
We studied 40 patients undergoing hemodialysis treatments
between February 2017 and January 2019. All patients were
dialyzed three times per week for 4 h with high-permeability
membranes. The blood flow was in the range of 250–300
mL/min with a dialysis rate flow of 500 mL/min. Oral iron
supplementation, based on ferrous citrate or an iron containing
phosphate binder was administered to all the participants. The
exclusion criteria were heart failure (NYHA III or IV), acute
myocardial infarction, and acute infectious disorders within
three months of recruitment. Patients were not obese and had
no severe malnutrition (BMI 20–30 kg/m2). After the initial
eligibility screening, subjects consuming zinc-salts and omega 3
dietary supplements were excluded. Involved patients voluntarily
provided the written informed consent to participate in this
research. This study was conducted in accordance with standards
and a principle stated in the Declaration of Helsinki and was
approved by the Ethical Review Board of the Military Medical
Academy, Belgrade, Serbia (Approval Project No 8/15-17).
Analysis of Biochemical Parameters
All blood samples were obtained immediately before the mid-
week dialysis session after a 12-hour fast. The following
serum parameters were considered: urea, creatinine, and
potassium, C-reactive protein (CRP), hemoglobin (Hb), total
cholesterol, HDL- and LDL-cholesterol, triglycerides, albumin,
iron, vitamin D, and intact parathyroid hormone (iPTH). After
the dialysis procedure serum urea, creatinine and potassium
analyses were repeated. Concentrations of biochemical blood
parameters were obtained spectrophotometrically using the
Siemens Dimension Rxl Max analyzer. The value of CRP was
calculated via enhanced turbidimetric-immunoassay (PETIA)
using the Siemens Dimension RxlMax analyzer. The Kt/V value
quantifying the hemodialysis efficiency was calculated using the
formula proposed by Daugirdas and Blake (38). Aliquots of the
remaining serum were made immediately, and these samples
were stored at −80 ◦C for further analysis of trace metal profiles
(zinc, copper) and fatty acids.
Anthropometric Measurements
Assessment of anthropometric parameters included height,
weight, mid-arm circumference (MAC) and waist circumference
(WC). Measurement was performed with individuals wearing
light clothes, without shoes. Height was measured using wall-
mounted stadiometer to the nearest 0.5 cm. Body weight and %
of body fat was measured using a body composition analyzer
InBody720 (Biospace Co., Ltd., Seoul, Korea). Visceral fat area
(VFA) was measured at the level of the umbilicus with a
dual bioelectrical impedance analyzer (DUALSCAN, Omron
Healthcare Co, Kyoto, Japan). WC was measured from the
midpoint between the lateral iliac crest and the lowest rib to the
nearest 0.5 cm. The visceral adiposity index (VAI) was calculated
using the formula by Amato et al. (39).
Assessment of Dietary PUFA, Zinc and
Copper Intake
Dietary intake evaluation was based on participants’ subjective
retrospective report, using the repeated 24-h recalls as the
assessment method. Complete consumption of food and
beverages was recorded on three occasions (dialyses day, one
non-dialyses weekday and one non-dialyses weekend day) for
each individual. Data was collected within in-depth multiple-
pass direct structured interviews administered by skilled survey
staff. Quantities of food consumed were estimated in reference
to common household measures, natural units, and standard
measuring kitchen tools as well as container size or packaging
information for commercial products. Regionally specific,
previously validated Food Atlas containing 135-items (simple
foods and composite dishes) was applied as an additional two-
dimensional portion-size estimation aid (40). Questionnaires
were processed and analyzed via Diet Assess & Plan, an
advanced nutritional software tool (41). Conversion of food to
nutrient intake was performed based on mean values for three
recall replicates and all the listed food items were matched
and coded using the national Serbian Food Composition
Database (42) in the Institute for Medical Research. Estimates
of zinc intake were compared against reference values proposed
specifically for hemodialysis patients, i.e.10–15mg for men
and 8–12mg for women (43, 44). Adequacy assessment for
copper intake was based on European Food Safety Authority
(EFSA) recommendations for general population (1.3 mg/day for
women, 1.6 mg/day for men) (45).
Fatty Acid Determination and Estimation of
Desaturase Activity
Total serum lipids were extracted according to the method of
Folch (46). As previously described, plasma phospholipids were
isolated by one-dimensional thin-layer chromatography (TLC) in
neutral solvent system hexane-diethyl-ether acetic acid (87:12:1
v/v) using Silica Gel GF plates (C. Merck, Darmstadt, Germany)
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and trans esterified to methyl fatty acid (47). Afterwards,
phospholipids’ fatty acid methyl ester samples were analyzed by
gas–liquid chromatography on the Shimadzu chromatograph GC
2014 (Kyoto, Japan), equipped with a flame ionization detector
on an Rt × 2330 column (60m × 0.25mm ID, film thickness
of 0.2µm; RESTEK, Bellefonte, PA, USA) with initial oven
temperature 130 ◦C held for 10min and then programmed to
increase at 3 ◦C/min to a final oven temperature of 220 ◦C. Fatty
acid methyl esters were identified by comparing peak retention
times with retention times obtained for fatty acids components
of standard mixtures PUFA−2 and/or 37 FAMEs mix (Supelco,
Bellefonte, PA, USA). The relative abundances of individual
fatty acids were calculated and expressed as a percentage
of total identified FAs. Activities of fatty acid desaturases
(D) were estimated as ratios of their relative abundances as
follows: 18:1n-9/18:0 for stearoil-CoA D18(SCD-18), 16:1n-
7/16:0 stearoil-CoA D16 (SCD-16), 20:3n-6/18:2n-6 for delta-6D
(D6D), 20:4n-6/20:3n-6 delta- (D5D) and 22:5n-3/20:5n-3 for
elongase (ELO) (48).
Serum Zinc and Copper Determination
Serum samples were prepared according to Stojsavljević et
al. (49). All chemicals used were of high grade and were
supplied by Merck (Darmstadt, Germany). Briefly, all samples
for metal analysis were diluted ten times with an aqueous
solution containing 0.05% nitric acid, 0.1% Triton X-100, and
3% 1-butanol. Copper and zinc were determined by inductively
coupled plasma-mass spectrometry (ICP-MS) in the collision
mode with internal standardization. Linearity of the calibration
curve above 0.999 was obtained for both trace metals in the range
from 1 to 250µg/L. The accuracy of the method used, expressed
as recovery and determined by analysis of standard reference
material (SeronormTM Trace Elements Serum L-2), was from 95.2
to 103.3% for 65Cu and from 96.2 to 102.7% for 66Zn. Serum zinc
concentration below 60 µg/dL was defined as zinc deficient (50).
Statistical Analysis
Complete Statistical analysis was performed with IBM SPSS 23
software package (Chicago, IL, USA) and principal component
analysis (PCA) in PLS ToolBox, v.6.2.1, Matlab 7.12.0 (R2011a)
statistical package. The distribution of data was evaluated using
Shapiro-Wilk’s test and Grubbs’ test-a and principal PCA to
test outliers. Performed test showed that there were no outliers.
The results obtained were presented as the mean value ±
standard deviation (SD) for normally distributed, and medians
(interquartile range) for scattered variables. Mean values of
normally distributed data were compared by unpaired Student’s
t-test and non-parametric Mann-Whitney test was performed
on non-transformed scattered values data. A logarithmic
transformation was performed for scattered variables prior to
further analyses with Pearson’s/Spearmen’s test for correlation
analysis. For all the analyses a p-value < 0.05 was considered
indicative for statistical significance.
RESULTS
Dietary Zinc, Copper and PUFA Intake in
Hemodialysis Patients
Forty participants with a mean age of 56 ± 15 years were
enrolled in the present study. The sample comprised thirty-
one (78%) male and nine female (22%) hemodialysis (HD)
patients. As it is shown in Table 1, 22 (55%) participants
had inadequate dietary zinc intake compared to recommended
values for HD patients (10–15 mg/day for men, 8–12 mg/day
for women). Distribution of food groups of zinc dietary
sources among study participants, based on 24 h recalls, is
presented in Figure 1. Biomarker analyses revealed that all
HD patients had zinc deficiency (i.e. serum zinc concentration
below the 60 µg/dL threshold) with a mean value of 38.8 ±
7.8 µg/dL. Accordingly, patients’ subdivision into categories
based on zinc status was not possible. With a median value
of 629 mg/day, copper intake was significantly below the
recommended level for the general population (45). Serum
copper concentration and the Cu/Zn ratio were 97.3 µg/dL and
2.8, respectively (Table 1).
Dietary intake data of HD patients is presented in Table 1.
Considering the estimated dietary intake of PUFA, the nutritional
n-6/n-3 ratio was notably high among HD patients. The
median contribution of PUFA to total energy intake was
6.84 ± 3.28%. Further data analyses indicated higher n-
3 PUFA intake among HD patients with adequate zinc
intake in comparison with those whose intake was below the
recommendations: 0.69 (0.56–0.94) vs. 0.53 (0.39–0.69) g/day.
This difference reach statistical significance (p = 0.028). There
were no differences for n-6, n-6/n-3, total PUFA and copper
intake comparing these groups (Table 1). Group comparison
based on zinc intake adequacy revealed that HD patients
with appropriate dietary zinc intake had higher caloric intake
(p = 0.03), protein (p = 0.003), SFA (p = 0.005), and
MUFA (p= 0.012).
To acknowledge the impact of diverse dietary sources on zinc
bioavailability and subsequent status, the contribution of various
food groups to total zinc intake is presented in Figure 1A. In this
study, the main dietary source of zinc were food items belonging
to meat and meat product group with mean contribution of 3.26
mg/day, representing 34.72% of the total estimated dietary intake
of zinc, so we presented the distribution of zinc daily intake from
foods from meat and meat products group in Figure 1B. In this
food group, a dominant source was beef meat, followed by pork
and chicken meat. Based on food consumption analysis, other
major sources were grains and grain products, miscellaneous
food products, as well as milk, milk products and substitutes
with 14.03, 13.77 and 10.39% contribution, respectively. In the
miscellaneous product group important zinc dietary sources were
bakery yeast and seasonings such as powdered red paprika,
dried parsley leaves, ground nutmeg, and powdered garlic.
Only 2.66% of total zinc intake was attributed to seafood and
related products.
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TABLE 1 | Demographic characteristic, dietary intake data, zinc and copper status in hemodialysis patients.
Variable All patients Adequate Zn intake Inadequate Zn intake
Age (years) 56 ± 15 56 ± 14 53 ± 15
Gender (M/F) n (%) 31/9 (78/22%) 15/3 16/6
BMI (kg/m2 ) 24.49 ± 3.76 25.09 ± 4.12 24.62 ± 3.44
HD duration (years) 5 (2–11.5) 3.5 (2–5) 5 (2–11)
Smokers/non-smokers n (%) 17/23 (42/58%) 9/9 8/14
Dietary zinc intake (mg/day) 9.35 ± 3.38 12.13 ± 2.56 7.07 ± 1.95***
M (RDI in HD 10-15 mg/day) 12.63 ± 2.49
F (RDI in HD 8-12 mg/day) 9.63 ± 2.10
M < 10 mg/day n (%) 16/31 (52%)
F< 8 mg/day n (%) 6/9 (67%)
Dietary copper intake (µg/day) 629 (425–774) 664 (512–799) 525 (402–749)
Energy intake (kcal/day) 1,858 (1,687–2,177) 2,093 ± 420 1822 ± 232*
Protein (g/day) 72.0 (59.0–87.7) 87.7 (78.9– 99.8) 63.6 (55.8–72.8)**
Carbohydrate (g/day) 230 ± 45 233 ± 62 228 ± 26
Total fiber (g/day) 19.5± 5.9 19.18 ± 5.33 19.77 ± 6.44
Fats (g/day) 79.8 ± 24.1 89.1 ± 18.5 70.9 ± 22.9**
SFA (g/day) 30.77 ± 12.04 38.42 ± 10.71 27.72 ± 11.25**
MUFA (g/day) 24.84± 7.57 31.06 ± 6.67 23.82 ± 9.11*
Dietary PUFA intake (g/day) 15.53 (8.72–20.00) 16.60 (9.07–19.96) 15.20 (7.18–26.02)
n−3 PUFA (g/day) 0.581 (0.507–0.836) 0.687 (0.560–0.942) 0.528 (0.394–0.688)*
n-6 PUFA (g/day) 12.60 ± 6.88 12.85 ± 5.96 12.39 ± 7.68
n-6/n-3 17.86 (10.16–29.00) 19.12 (10.20–27.07) 16.70 (10.12–36.72)
Serum
Zinc (µg/dL) 38.8 ± 7.72 35.2 ± 5.4 39.8 ± 9.3
Serum zinc deficiency
(< 60 µg/dL) n (%) 40 (100 %)
Correlation: Zn intake/status r = −0.200
p = 0.211
Copper (µg/dL) 973 (930–1,191) 1,037 (719–1,108) 980 (930–1,086)
Cu/Zn ratio 2.76 ± 0.68 2.85 ± 0.68 2.56 ± 0.51
Continuous variables are shown as means ± SD for a normal distribution or medians (interquartile range) for a non-normal distribution. HD, hemodialysis; RDI, recommended daily
intake; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; Cu, copper; Zn, zinc. *p < 0.05, **p < 0.01, ***p < 0.001 inadequate Zn
intake vs. adequate Zn intake.
Correlations of Biochemical and
Anthropometric Parameters With Zinc
Intake and Status
Group comparison based on zinc intake adequacy revealed that
HD patients with appropriate dietary zinc intake had lower
iPTH concentrations (p = 0.047), VAI values (p = 0.020)
and higher MAC (p = 0.031) (Figures 2A–C). There were
no other statistically significant differences in biochemical and
anthropometric parameters between these two groups.Moreover,
further analysis of obtained data showed that there are significant
correlations between dietary zinc intake and iPTH, VAI andMAC
values (Table 2). The only significant difference in the fatty acid
profile in HD patients with inadequate zinc intake was a lower
level of n-3 PUFA compared to HD patients with adequate zinc
intake (Table 3). Nevertheless, low EPA+DHA values and high
n-6/n-3 ratio were present in both groups.
Table 4 represents the associations of biochemical and
anthropometrics parameters with dietary intake of zinc, serum
zinc and copper status. Dietary zinc intake did not correlate with
serum zinc concentration in HD patients (data not shown). The
inverse associations were found between zinc intake estimates
and LDL cholesterol (r = −0.332, p = 0.036) as well as iPTH
levels (r = −0.317, p = 0.046) (Table 4). Dietary intake of
zinc was directly associated with the anthropometric parameter
MAC and inversely with VAI (p < 0.05, for both parameters).
There were no significant correlations between the serum zinc
concentrations and analyzed biochemical parameters. However,
significant inverse correlations between the serum Cu/Zn ratio
and serum albumin (r = −0.404, p = 0.009), iron (r = −0.351,
p = 0.026), PTH (r = −0.332, p = 0.036) concentration and
Kt/V (r =−0.317, p= 0.046) were noted. In addition, the serum
Cu/Zn ratio was directly associated with HD period (r = 0.355,
p= 0.023), CRP (r= 0.315, p= 0.048), BMI (r= 0,384, p= 0.014)
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FIGURE 1 | (A) Dietary sources of zinc intake by food groups and (B) Distribution of zinc intake for meat and meat product in hemodialysis patients.
FIGURE 2 | Differences in clinical and anthropometric parameters comparing groups with adequate and inadequate dietary Zn intake. (A) Median values for intact
parathyroid hormone (iPTH) levels (1st-3rd interquartile for inadequate Zn intake = 36–75.9; 1st-3rd interquartile for adequate Zn intake = 19–47.3), (B) Median values
for mid-arm circumference (MAC) (1st-3rd interquartile for inadequate Zn intake =23.7–26.5; 1st-3rd interquartile for adequate Zn intake = 25.6–29.55), and (C) Mean
± standard deviation for visceral adiposity index (VAI). *p < 0.05 for inadequate Zn intake vs adequate Zn intake.
and VFA (r = 0.327, p = 0.040). Serum copper concentration
directly correlated with BMI (r = 0.384, p = 0.014) and VFA (r
= 0.361, p= 0.023) and inversely correlated with serum albumin
concentration (r =−0.449 p= 0.004).
Correlations of PUFA and Estimates of
Desaturase Activity With Zinc Status
As shown in Table 5, no statistically significant correlations
were observed between dietary zinc intake and plasma
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TABLE 2 | Characteristic of the hemodialysis patients.
Variable All patients Adequate Zn intake Inadequate Zn intake
Hg (g/L) 101.0 ± 15.2 102.8 ± 11.8 102.6 ± 18.3
Urea (mmol/L) 23.9 ± 4.8 24.1 ± 5.8 23.3 ± 4.7
Creatinine (µmol/L) 913 ± 147 967 ± 135 876 ± 161
Kt/V 1.47 ± 0.32 1.34 ± 0.27 1.49 ± 0.37
Protein (g/l) 67.5 (63–70) 68 (66.5–69) 67.5 (63–70)
Albumin (g/l) 37.5 (36–40) 37 (35–39) 38 (37–40)
Total cholesterol (mmol/L) 4.52 ± 0.92 4.73 ± 0.92 4.40 ± 1.35
LDL cholesterol (mmol/L) 3.09 ± 0.78 2.95 ± 0.82 3.19 ± 0.93
HDL cholesterol (mmol/L) F: 0.995 (0.91–1.08) F: 0.955 (0.91–1) F: 1.41 (1.09–1.46)
M: 1.065 (0.90–1.29) M: 1.185 (0.98–1.4) M: 0.9 (0.64–1.14)
Triglycerides (mmol/L) 1.21 (1.025–1.575) 1.11 (1.02–1.51) 1.50 (1.00–1.93)
Tg/HDL 1.28 (0.91–1.69) 1.10 ± 0.48 1.52 ± 0.73
CRP ≤ 3 mg/L n (%) 12 (42%) 6/12 6/16
CRP > 3 mg/L n (%) 28 (58%)
WC (cm) F: 82.1 ± 10.8 F: 78.5 ± 11.3 F: 87.1 ±8.8
M: 95.6 ± 11.4 M: 96.8 ±13.3 M: 94.5 ±9.5
% Body fat F: 30.6 ± 10.8 F: 28.2 ± 2.3 F: 29.1 ±5.3
M: 25.5 ± 8.4 M: 23.7 ±9.4 M: 26.1 ± 8.0
MAC (cm) 25.6 ± 3.8 27.25 (25.6–29.55) 25.1 (23.7–26.5)*
VFA (cm2) 96.2 ± 44.6 93.2 ± 55. 102.7 ± 32.2
VAI 2.00 ± 1.01 1.58 ± 0.75 2.44 ± 1.09*
Iron (µmol/L) 14.8 ± 5.3 13.8 ± 4.4 15.2 ± 6.1
iPTH (pg/ml) 43.45 (19.4–64.7) 32.3 (19–47.3) 52.8 (36–75.6)*
Vitamin D (nmol/L) 35.87 ± 9.81 35.46 ± 11.46 34.94 ± 8.03
Continuous variables are shown as means ± standard deviation for a normal distribution or medians (interquartile range) for a non-normal distribution. BMI, body mass index; F, female;
M, male; CRP, C-reactive protein; Hg, hemoglobin; Tg, Triglyceride; WC, waist circumference; MAC, mid arm circumference; VFA, visceral fat area; VAI, visceral adiposity index; iPTH,
intact parathyroid hormone. *p < 0.05 inadequate Zn intake vs adequate Zn intake, #distribution of data could not be tested as there are less than 5 data (n = 3).
phospholipids’ levels of individual n-6 and n-3 PUFAs neither
with estimated desaturase activities among HD patients.
Positive correlations were found for serum zinc concentration
with DGLA (r = 0.357, p = 0.024) and D6D (r = 0.311,
p = 0.037) and inverse associations with the DGLA/LA
ratio (r = −0.335, p = 0.033). Serum copper concentration
was inversely associated with EPA (r = −0.465, p = 0.03).
The Cu/Zn ratio and serum copper concentration directly
correlated with ELO (r = 0.384, p = 0.01 and r = −0.575, p <
0.001, respectively).
DISCUSSION
To the best of our knowledge, this is the first study evaluating
zinc status in hemodialysis patients, considering dietary zinc
intake, serum zinc levels and mutual relations with fatty acid
profile, and estimated desaturase activities. Among studied
patients, both zinc deficiency and altered Cu/Zn ratio were
observed. Inadequate dietary zinc intake was present up to
55% of hemodialysis patients and there was no significant
correlation between the estimated intake and serum zinc
concentration. Based on our findings, zinc dietary intake did
not correlate with serum PUFA status and estimated desaturase
activity in hemodialysis patients. Furthermore, data revealed the
absence of association between serum zinc concentration and
analyzed biochemical parameters. It is noteworthy that all the
studied hemodialysis patients had zinc deficiency, determined
according to low serum zinc concentration as known as a
sensitive biomarker of zinc status. This led to no statistically
significant difference in the zinc levels and Cu/Zn ratio compared
hemodialyzed patients with adequate and inadequate zinc intake.
Results of this study indicate that the serum zinc and copper
concentrations and their ratio were related to modified fatty
acid PUFA profile in hemodialysis patients, with DGLA, EPA,
LA/DGLA and estimated D6D activity.
Our results are in accordance with previously published
data suggesting that hemodialysis patients have low serum
zinc concentration (5, 19–23). As reported in the present
study, dietary zinc intake is quite often not correlated with
plasma/serum zinc status (37, 51). Fifty-five percent of recruited
patients had zinc intake below the recommended level for
patients with CKD and all had zinc deficiency (defined as serum
concentration below 60 µg/dL). Severe zinc deficiency can
manifest clinically when its serum values decrease to 40 µg/dL.
Mean serum zinc concentration of 38.8 ± 7.72 µg/dL obtained
in these samples could be considered as indicative for zinc
supplementation. Although only 1% of total zinc in the body is
present in circulation, serum zinc is still regarded as an important
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TABLE 3 | Plasma fatty acid status in hemodialysis patients.
Fatty acid All patients Adequate Zn intake Inadequate Zn intake
% n = 18 n = 22
16:0 28.60 ± 1.94 28.44 ± 2.03 28.31 ± 2.28
18:0 19.06 (17.68–19.81) 17.80 (17.04–19.70–24.82) 19.36 (18.36–20.29)
SFA 47.52 ± 2.32 46.85 ± 2.22 47.96 ± 2.30
16:1n−7 0.38 (0.26–0.46) 0.36 (0.22–0.45) 0.40 (0.27–0.48)
18.1n-9 9.61 (8.54–10.25) 9.73 (8.38–10.19) 9.87 (8.86–10.44)
18:1n−7 1.85 (1.70–2.09) 1.73 (1.66–2.02) 1.95 (1.74–2.08)
MUFA 11.84 (11.03–12.68) 11.81 (10.72–12.20) 12.31 (11.22–12.87)
18:2n-6 (LA) 21.89 ± 3.14 22.22 ± 2.93 21.64 ± 3.99
20:3n-6 (DGLA) 2.87 ± 0.66 3.02 ± 0.74 2.94 ± 0.63
20:4n-6 (AA) 11.78 ± 2.25 12.14 ± 2.06 11.61 ± 2.62
22:4n-6 0.66 (0.50–0.90) 0.67 (0.46–1.01) 0.60 (0.45–0.71)
n-6 37.27 ± 3.03 38.12 ± 2.69 36.79 ± 7.48
18:3n-3 0.11 (0.08–0.16) 0.12 (0.08–0.15) 0.09 (0.07–0.19)
20:5n−3 (EPA) 0.22 (0.16–0.31) 0.24 (0.14–0.32) 0.18 (0.16–0.32)
22:5n-3(DPAn-3) 0.56 (0.48–0.69) 0.62 (0.48–0.80) 0.54 (0.44–0.59)
22:6n-3 (DHA) 2.26 ± 0.57 2.36 ± 0.62 2.08 ± 0.41
n-3 3.25 ± 0.74 3.42 ± 0.83 2.97 ± 0.51*
n-6/n-3 11.99 ± 2.54 11.71 ± 2.66 12.68 ± 2.20
EPA+DHA 2.51 ± 0.60 2.61 ± 0.63 2.29 ± 0.42
PUFA 40.52 ± 3.31 41.54 ± 2.71 39.77 ± 3.61
D5D 4.28 ± 1.15 4.20 ± 1.09 4.06 ± 1.11
D6D 0.128 (0.106–0.153) 0.129 (0.109–0.149) 0.127 (0.102–0.185)
SCD16 0.013 (0.009–0.016) 0.012 (0.008–0.016) 0.014 (0.010–0.016)
SCD18 0.49 (0.43–0.57) 0.53 (0.45–0.57) 0.49 (0.44–0.57)
LA/DGLA 8.10 ± 2.53 7.80 ± 2.17 7.79 ± 2.72
ELO 2.47 (0.96–11.0) 3.29 (3.10–11.00) 2.51 (1.00–5.17)
Continuous variables are shown as means ± standard deviation for a normal distribution or medians (interquartile range) for a non-normal distribution; SFA, saturated fatty acids; MUFA,
monounsaturated fatty acids; LA, linoleic acid; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic
acid; PUFA, polyunsaturated fatty acids; D5D, 1-5-desaturase; AA/DGLA (20:4 n-6/20:3 n-6), D6D, 1-6-desaturase: DGLA/LA (20:3 n-6/18:2 n-6); SCD16 and 18, stearoil-CoA
desaturase 16 and 18, ELO, elongase: (DPAn-3/EPA), *p < 0.05 inadequate Zn intake vs. adequate Zn intake.
biomarker and useful indicator of dietary zinc restriction,
zinc supplementation, and clinical deficiency. The recently
determined interval for serum zinc concentration in the adult
Serbian population (from 40 to 82,5 µg/ dL) strongly implies
that even our healthy population could be at risk to develop zinc
deficiency (52). Therefore, adequate oral zinc supplementation
and/or foodstuff fortification should be considered to prevent the
deleterious effects caused by zinc deficiency (53). It is important
to notice that meta-analysis by Wang et al. (54) showed that
zinc supplementation with median dose of 45 mg/day and
duration of median 60 days results in higher serum zinc levels
and lower CRP and malondialdehyde levels in hemodialyzed
patients. Thus, evidence supported that zinc supplementation
in doses that are much higher than recommended values for
dietary intake (8–12 mg/day for women, 10–15mg/day for
men) may improve serum zinc levels in hemodialysis patients.
Increasing number of CKD patients is considered a major
public health problem and there is the new evidence that low
dietary zinc intake may increase the risk of CKD development
in individuals with normal renal function (55). Low serum zinc
concentrations among hemodialysis patients are supposed to
result from zinc removal during the treatment itself, decreased
albumin levels, diminished gastrointestinal zinc absorption,
and antagonistic effects of copper to their common carrier –
metalothionine, due to its higher affinity to copper compared
to zinc (16, 56). In addition, a high intake of copper, iron or
phytic acid could cause malabsorption of dietary zinc (57).
The molar ratio of phytate and zinc has been shown to be a
predictor of zinc absorption; however, data for dietary amounts
of phytic acids are still scarcely available in food composition
databases. A nutrition plan targeting plant-based food was
not recommended to studied hemodialysis patients due to
the high content of potassium and phosphates. Given that the
major contributor to zinc intake were meat and meat products,
participants of the present study dominantly obtained zinc
from high bioavailability sources. Group comparison based
on zinc intake adequacy revealed that our hemodialysis
patients with appropriate dietary zinc intake had daily
higher energy, protein, total fats and SFA, MUFA and n-3
PUFA consumption.
























TABLE 4 | Correlation between zinc intake and status values with the different biochemical parameters in hemodialysis patients.




r 0.021 −0.078 −0.140 −0.168 −0.132 −0.120 0.222 0.202 0.051 −0.332 −0.039 −0.168 −0.317 0.087 0.005 0.449 0.088 −0.317
p 0.899 0.629 0.388 0.300 0.415 0.460 0.170 0.211 0.750 0.036 0.809 0.300 0.046 0.589 0.977 0.004 0.589 0.046
Serum
Zn
r 0.113 0.021 0.009 −0.089 0.132 −0.118 0.032 0.118 −0.039 0.051 0.083 0.001 0.113 0.021 0.083 0.010 0.113 0.069
p 0.486 0.900 0.955 0.582 0.415 0.469 0.842 0.470 0.809 0.753 0.611 0.998 0.485 0.896 0.611 0.925 0.485 0.669
Serum
Cu
r 0.118 −0.214 0.231 0.010 −0.256 −0.032 0.118 −0.449 0.056 −0.064 0.010 −0.021 −0.177 −0.038 0.383 0.185 0.361 0.094
p 0.470 0.183 0.151 0.950 0.111 0.842 0.470 0.004 0.729 0.696 0.950 0.900 0.273 0.815 0.015 0.252 0.023 0.560
Cu/Zn
r 0.118 −0.214 0.231 0.010 −0.256 −0.032 0.118 −0.449 0.056 −0.064 0.010 −0.021 −0.177 −0.038 0.383 0.185 0.361 0.094
p 0.415 0.026 0.048 0.023 0.046 0.454 0.879 0.009 0.683 0.522 0.539 0.751 0.029 0.720 0.016 0.155 0.040 0.770
Alb, albumin; sCr, serum creatinine; HD per, hemodialysis period; TC, total cholesterol.
TABLE 5 | Correlation between Zinc intake and status values with plasma PUFA profile and estimated desaturase activity in hemodialysis patients.




r 0.173 0.213 0.133 0.023 0.026 −0.048 0.007 0.058 −0.092 0.011 −0.025 −0.036 0.054 0.073
p 0.284 0.182 0.406 0.892 0.874 0.742 0.955 0.729 0.564 0.947 0.883 0.827 0.761 0.668
Serum
Zn
r −0.125 −0.218 0.357 0.250 −0.292 −0.052 0.165 −0.112 −0.168 0.331 −0.335 −0.229 −0.183 0.220
p 0.442 0.174 0.024 0.118 0.064 0.748 0.307 0.491 0.296 0.037 0.033 0.155 0.277 0.168
Serum
Cu
r −0.032 −0.147 0.256 0.089 −0.465 0.079 0.060 −0.027 −0.215 0.181 −0.202 0.165 −0.202 0.575
p 0.842 0.365 0.111 0.583 0.003 0.627 0.704 0.868 0.184 0.263 0.211 0.310 0.211 <0.001
Cu/Zn
r 0.118 0.021 −0.023 −0.118 −0.364 0.093 −0.060 0.036 −0.087 −0.070 0.063 0.035 −0.027 0.384
p 0.470 0.899 0.907 0.470 0.090 0.566 0.715 0.827 0.589 0.666 0.697 0.829 0.867 0.014
LA, linoleic acid; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; ALA, alfa-linolenic acid; EPA, eicosapentaenoic acid, DHA, docosahexaenoic acid; D5D, 1-5-desaturase; AA/DGLA (20:4 n-6/20:3 n-6); D6D, 1-6-desaturase;
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It is assumed that disruption of zinc and copper levels could
be the cause of clinical deterioration as well as negative outcomes
in hemodialysis patients. Previous findings indicated that the
increased plasma Cu/Zn ratio reflects the disturbance in zinc and
copper homeostasis and could be applied as a clinical predictor
for patients’ inflammatory status (10). It is suggested that the
optimum serum Cu/Zn-ratio lies between 0.7 and 1.0 (58).
Participants in the present study exhibited abnormally increased
Cu/Zn-ratio with a mean value of 2.76 ± 0.68. Trendafilov et
al. (56) found a negative correlation between zinc status and
markers of inflammation (CRP and IL-6), and a direct association
of these parameters with copper status. Given the association
found with the CRP as an indicator of the inflammatory
response, clinical significance of Cu/Zn ratio for treatment
outcome and further progression of renal failure is evident in our
study population.
According to the European Society for Clinical Nutrition
and Metabolism guideline for hospitalized patients with acute
or CKD, zinc and copper levels should be measured for
nutrition screening and supplemented accordingly (59). There is
evidence implying that serum zinc concentration is reduced by
hypoalbuminemia in CKD patients, as zinc is bound to albumin
in the circulation (60). Our study showed that the Cu/Zn ratio
is inversely correlated with albumin levels. This study did not
identify such associations between serum zinc concentration
and explored biochemical parameters. This might be due to the
limited sample size, which resulted in low statistical power for
detecting outcomes of the serum zinc variable. The Cu/Zn ratio
has been recognized as a better indicator of the significance
of zinc deficiency than the concentration of zinc and copper
in serum separately. In the present study inverse association
between the serum Cu/Zn ratio and serum iron and iPTH
concentration was observed among hemodialysis patients.
Zinc deficiency is suspected to cause an increase in PTH
due to its contribution in maintaining calcium homeostasis
(61). Previously published studies showed a significant negative
correlation between serum levels of iPTH and zinc in
hemodialyzed children (62), but this correlation was not
highlighted for the adult patient population (63). Based on
our findings, estimated dietary zinc intake and Cu/Zn ratio
were inversely associated with serum concentrations of iPTH,
but there was no significant association between serum zinc
levels and iPTH levels. Taken all together, our results indicate
that zinc intake and its status together with Cu/Zn balance in
serum are associated with iPTH levels and consequently calcium
homeostasis. The mechanism of PTH effects on plasma zinc
concentration in CKD was investigated by Chen et al. (64) who
found that PTH enhanced extra renal zinc disposal and increased
zinc uptake by liver, suggesting that the over-secretion of PTH
could be present in zinc deficiency. Furthermore, low vitamin D
status leads to reduced efficiency of intestinal calcium absorption,
and the body reacts by increasing the secretion PTH. Prescription
of activated vitamin D to a CKD patient with high PTH levels
is, therefore, a justified clinical solution. It is noteworthy that
all the studied patients in our sample had vitamin D deficiency.
Nevertheless, serum vitamin D levels did not correlate with
zinc status.
Previously published data revealed that zinc supplementation
could significantly reduce total cholesterol, LDL-cholesterol,
and triglycerides in the general population (63). However, a
recent meta-analysis showed no effect on the lipid profile
of zinc supplementation in patients subjected to maintenance
hemodialysis (54). A statistically significant inverse association
was found between LDL-cholesterol levels and estimated dietary
zinc intake, but no significant relationships were found with
serum zinc concentration and Cu/Zn ratio. We obtained
significant differences for iPTH, VAI, and MAC between the
groups with adequate and inadequate dietary zinc intake, and
its association with these parameters. However, we did not
obtain correlations of iPTH, VAI, and MAC with serum zinc
concentration. This could indicate the influence of deviations
of zinc homeostasis and redistribution in tissue and cell (e.g.
zinc concentration in erythrocytes). Some authors declare that
it is not clear yet whether low serum/plasma zinc levels in
CKD patients represent genuine deficiency or its low levels are
due to redistribution in different biological compartments (65).
Recently, serum zinc levels were found to positively correlate
with the nutritional status assessed by measuring abdominal
fat area using computed tomography in patients with advanced
CKD undergoing hemodialysis (66). In our study, no statistically
significant correlations were determined between the serum
zinc level concentration and anthropometric measurements.
Nevertheless, based on our observations, the Cu/Zn ratio
positively correlated with BMI and VFA. Furthermore, the results
of our study indicated that dietary zinc intake directly correlated
with the MAC and inversely with VAI, a reliable indicator of
visceral fat function associated with cardiometabolic risk. There
is substantial evidence that higher BMIs are associated with an
increased risk of CVD and mortality in the general population,
but a reverse relationship is observed in HD patients and this
phenomenon is known as the “risk factor paradox” (67). It is,
however, unclear whether the survival advantage associated with
higher BMIs among hemodialysis patients is caused by increased
muscle mass, fat mass, or both. Previous findings indicated
that zinc supplementation increase body weight and BMI in
hemodialysis patients (68, 69).
Blood fatty acid composition seems to be an independent
risk factor for CVD in patients subjected to HD (34, 70–72). It
reflects both nutritional intake and endogenous synthesis of fatty
acids, but there is still not much available information on dietary
fatty acid intake in patients undergoing hemodialysis. In a recent
study, Khor et al. (73) reported suboptimal dietary intake of
PUFAs (<5% of total calories). The American Heart Association
recommends replacing saturated fatty acids with PUFAs (>10%
of total calories) for the general population to reduce the risk for
CVD (74). Inadequate intake of total PUFAs was found in 50%
of hemodialysis patients in this study. The mean dietary intake
of fish and seafood was 10.5 g/day i.e. 73.5 g/week. These findings
suggest suboptimal intake of n-3 PUFA as well, since two servings
of fish (180g) a week is recommended (75). Based on Wijendran
et al. (76), if the consummation of LA, ALA, EPA+DHA were
in accordance with the recommendations, the dietary n-6/n-3
ratio should be approximately 6. In the present study 33 of 40
participants had a higher dietary n-6/n-3 PUFA ratio. Therefore,
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dietary habits of studied hemodialysis patients indicate the need
for better nutritional strategies to achieve adequate fatty acid
status. However, adequate zinc intake in our study population
was accompanied with significantly higher intake of energy, total
fats, SFA, MUFA and protein. According to results of our study
red meat represented the main dietary source of zinc. Red meat
represents a rich dietary source of zinc and proteins but also other
nutrients such as SFA and cholesterol, limiting of its consumption
is proposed strategy to reduce CVD risk in CKD patients, making
even more difficult to reach adequate zinc intake by diet (77).
Currently, there is no consensus in nutrition guidelines for
the optimal dietary fatty acid intake targeting specifically CKD
patients, but high dietary intake of zinc by consumption of
foods abundant in zinc may lead to overconsumption of SFA.
According to results of this study the zinc supplementation in
CKD patients on hemodialysis, may be necessary to improve
serum zinc status as the patients with adequate dietary zinc intake
are shown to be zinc deficient, but could be a good strategy to
ensure adequate zinc intake without high intake of some other
nutrients such as SFA. Due to the recommended restriction of
animal protein intake in patients with CKD supplementation is
indicative for resolving zinc deficit in patients on hemodialysis.
A recent systematic review regarding the blood fatty acid
status in dialysis patients from different countries revealed that
the reported diversity of n-3 PUFA levels could be attributed
to the variety of dietary habits (78). Among participants
in this study, very low levels of EPA+DHA were observed
in serum phospholipids. These findings are not unexpected
since the dietary intake of fish and seafood was significantly
below the recommendations. Our previous studies have already
demonstrated markedly low n-3 PUFA status in dialyses
population as well as its association with other clinical
parameters, especially inflammation markers (29, 47, 79). This
current study indicates that besides low n-3 PUFA status their
dietary intake is also inadequate and accompanied by high n-6/n-
3 ratio.
Essential fatty acids LA and ALA cannot be synthesized
in humans and must be provided by the diet. However, they
can be metabolized to long-chain PUFAs. DGLA, AA, and
22:4n-6 are the major products of LA desaturation/elongation
metabolic pathway, while the ALA can be converted to EPA,
DPAn-3, and DHA. Although these conversions seem to be
relatively inefficient in humans, our previous research suggested
beneficial effects of administration of ALA-rich seed mixture for
improving EPA and DHA levels in hemodialysis patients (47).
In fact, in the recent study authors hypothesized that uremic
milieu found in hemodialysis patients could affect the n-3 PUFA
metabolic pathway (73). Previous investigations have shown that
serum/plasma zinc and copper levels could be associated with
LA/DGLA values in healthy, dyslipidemic obese subjects, and
children (35, 37, 80). To our best knowledge, there is no literature
data regarding the relationship between zinc and copper status
with estimates of desaturase activities and relative abundance of
individual PUFA in HD population.
In the present study, zinc status was low in all patients
undergoing hemodialysis, but the finding that it is directly
associated with D6D is not unexpected. The inverse association
between serum zinc status and LA/DGLA ratio has been
determined in healthy subjects and dyslipidemic obese adult
subjects, as well as children (35, 37, 80). Therefore, LA/DGLA
was proposed as an emerging candidate biomarker for zinc
status assessment (37). The obtained statistically significant
inverse relationship between serum zinc concentrations and
LA/DGLA confirms sensitivity of this biomarker in zinc deficient
population. In line with other studies, we also found that DGLA
levels were positively correlated with zinc status (35, 37). This
fatty acid can be metabolized to one series of prostaglandins
which possess anti-inflammatory properties, unlike two series
of prostaglandins produced from AA generally viewed as pro-
inflammatory (69). AA/DGLA ratio which is generally elevated
in chronic renal patients undergoing HD is regarded as an
important predictor of poor clinical outcomes (72). In this
study, copper levels correlated inversely with EPA levels and
directly with estimates of ELO activity, while the Cu/Zn ratio
directly correlated with ELO activity and was not associated
with EPA levels. These findings could be important as there is
no literature data for copper status association with EPA levels
and estimated ELO activity and scientific evidence suggests that
EPA supplementation could decrease the all-cause mortality in
patients undergoing HD treatment (71).
Based on a contrite meta-analysis of early and preliminarily
available data, CKD seems to be associated with enhanced risk
of severe COVID-19 infection. Multiple aspects of the immune
system are affected by zinc. The prevalence of CKD in COVID-
19 patients has been reported to be about 0.09–47.1% (81).
Novel data suggest that oral zinc supplementation (80 mg/day
of elemental zinc) administered at the first signs and symptoms
of COVID-19 could be a promising therapeutic strategy (82).
In general, a large body of evidence shows that up to one year
of zinc supplementation in doses of 220 mg/d to 660 mg/d in
chelated form (corresponding to approximately 50mg to 150mg
of elemental zinc) seems to be a safe regimen for patients with
CKD (54). Recently published studies demonstrated that the
administration of oral zinc acetate could increase a risk for
copper deficiency in hypoalbuminemic hemodialysis patients
(83). A personal nutrition therapeutic approach is necessary
for patients with CKD and hemodialysis sessions represent a
valuable opportunity to monitor nutritional status and prescribe
the appropriate interventions (84–86).
LIMITATIONS
Several limitations of this study should be acknowledged. First,
the sample size was relatively small, and our findings should
be confirmed and clarified by further larger-scale studies. All
involved hemodialyzed patients were zinc deficient, so it was
not possible to divide them into groups according to serum
zinc levels. Second, dietary intake of zinc, copper and fatty acids
were estimated using self-reported, retrospective 24 h nutritional
surveys. All methods for the assessment of dietary exposure
have their inherent limitations and 24 h surveys may not be the
best nutritional tool to estimate the consumption of foods that
are not consumed on a daily basis, such as fish, seafood, and
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seafood products. Finally, statistical analysis was not performed
with sex-specific considerations since female participants were
underrepresented with only 20% in the studied patient group.
Zinc deficiency could cause changes in a plethora of biochemical
and clinical parameters that reflect renal function, the efficiency
of hemodialysis treatment, dyslipidemia, calcium homeostasis
(iPTH and vitamin D), body composition, inflammatory status,
and anemia. In addition to factors explored in this study, there
are other important parameters such as glucose homeostasis,
redox status, and immune function that are relevant for patients
undergoing HD, and further research is needed to provide a
better understanding of their relationships with zinc status.
CONCLUSION
In conclusion, due to the observed zinc deficiency in
hemodialysis patients, it is necessary to determine serum
zinc levels together with the Cu/Zn ratio as a standard in
screening nutritional status. These indices could play an
important role in desaturation/elongation of PUFA in this
patient population group. Our results underline the need for
zinc supplementation in patients undergoing hemodialysis as
all patients had suboptimal serum status of zinc including those
with adequate dietary intake. Zinc supplementation with high
doses that cannot be provided by diet in hemodialysis patients
in combination with n-3 PUFA supplements potentially could
induce even more favorable change in fatty acids profiles than
n-3 PUFAs treatments alone. Importantly, zinc deficiency with
an altered n-3 fatty acid profile can affect disease progression
and associated with various risk for CVD. More interventional
studies are warranted to confirm the benefits of zinc and PUFA
supplementation in hemodialysis patients for the prevention and
attenuation of adverse health outcomes.
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G, Mutić J, et al. Determination of toxic and essential trace elements in
serum of healthy and hypothyroid respondents by ICP-MS: a chemometric
approach for discrimination of hypothyroidism. J Trace ElemMed Biol. (2018)
48:134–40. doi: 10.1016/j.jtemb.2018.03.020
50. Yokokawa H, Fukuda H, Saita M, Miyagami T, Takahashi Y, Hisaoka
T, et al. Serum zinc concentrations and characteristics of zinc
deficiency/marginal deficiency among Japanese subjects. J Gen Fam Med.
(2020) 21:248–55. doi: 10.1002/jgf2.377
Frontiers in Nutrition | www.frontiersin.org 13 September 2021 | Volume 8 | Article 700450
Takic et al. Zinc and PUFA in Hemodialysis
51. King JC, Brown KH, Gibson RS, Krebs NF, Lowe NM, Siekmann JH, et al.
Biomarkers of nutrition for development (bond)-zinc review. J Nutr. (2016)
146:858S−85S. doi: 10.3945/jn.115.220079
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